新掌门首份成绩单亮眼：HIV与抗癌药立功葛兰素史克(GSK.US)Q1营收利润双超预期

智通财经04-29

智通财经APP获悉，得益于HIV、癌症及免疫疾病领域的专科药物销售表现强劲，英国制药巨头葛兰素史克(GSK.US)周三公布了超预期的第一季度财报，这为年初正式掌舵的新任首席执行官Luke Miels带来了有力支持。财报显示，截至3月31日，葛兰素史克实现营收76.3亿英镑(约合103亿美元)，略高于市场预期的75.8亿英镑。核心每股收益达46.5便士(约合63美分)，优于分析师共识预期的43.3...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2631056182?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-29 14:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631056182","market":"hk","top_or_hot":-1,"title":"新掌门首份成绩单亮眼：HIV与抗癌药立功 葛兰素史克(GSK.US)Q1营收利润双超预期","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，得益于HIV、癌症及免疫疾病领域的专科药物销售表现强劲，英国制药巨头葛兰素史克(GSK.US)周三公布了超预期的第一季度财报，这为年初正式掌舵的新任首席执行官Luke Miels带来了有力支持。财报显示，截至3月31日，葛兰素史克实现营收76.3亿英镑(约合103亿美元)，略高于市场预期的75.8亿英镑。核心每股收益达46.5便士(约合63美分)，优于分析师共识预期的43.3...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1436066.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新掌门首份成绩单亮眼：HIV与抗癌药立功 葛兰素史克(GSK.US)Q1营收利润双超预期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新掌门首份成绩单亮眼：HIV与抗癌药立功 葛兰素史克(GSK.US)Q1营收利润双超预期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-29 14:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1436066.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，得益于HIV、癌症及免疫疾病领域的专科药物销售表现强劲，英国制药巨头葛兰素史克(GSK.US)周三公布了超预期的第一季度财报，这为年初正式掌舵的新任首席执行官Luke Miels带来了有力支持。财报显示，截至3月31日，葛兰素史克实现营收76.3亿英镑(约合103亿美元)，略高于市场预期的75.8亿英镑。核心每股收益达46.5便士(约合63美分)，优于分析师共识预期的43.3...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1436066.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1436066.html","article_id":"2631056182","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631056182","pubTimestamp":1777445657,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，得益于HIV、癌症及免疫疾病领域的专科药物销售表现强劲，英国制药巨头葛兰素史克周三公布了超预期的第一季度财报，这为年初正式掌舵的新任首席执行官Luke Miels带来了有力支持。财报显示，截至3月31日，葛兰素史克实现营收76.3亿英镑，略高于市场预期的75.8亿英镑。自宣布Miels接任CEO以来，葛兰素史克股价已累计上涨约34%，显示出市场对其变革举措的初步认可。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"GSK":"葛兰素史克"},"translate_title":"The first report card of the new head is eye-catching: HIV and anti-cancer drugs have made contributions GlaxoSmithKline (GSK.US) Q1 revenue and profit both exceeded expectations","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1.5},"content_text":"智通财经APP获悉，得益于HIV、癌症及免疫疾病领域的专科药物销售表现强劲，英国制药巨头葛兰素史克(GSK.US)周三公布了超预期的第一季度财报，这为年初正式掌舵的新任首席执行官Luke Miels带来了有力支持。财报显示，截至3月31日，葛兰素史克实现营收76.3亿英镑(约合103亿美元)，略高于市场预期的75.8亿英镑。核心每股收益达46.5便士(约合63美分)，优于分析师共识预期的43.3便士。这标志着Miels自1月1日接任以来的首个完整季度。这位曾任公司首席商务官的新掌门人，正面临重塑公司管线的重大考验。葛兰素史克关键HIV药物Dolutegravir的专利将于2028年到期，Miels肩负着通过加强新药管线来弥补潜在收入损失的重任，以证明公司研发引擎有能力实现2031年营收超过400亿英镑的长期目标。自宣布Miels接任CEO以来，葛兰素史克股价已累计上涨约34%，显示出市场对其变革举措的初步认可。从本季度的增长引擎来看，公司的专科药物业务表现强劲。用于治疗子宫内膜癌的Jemperli和用于预防HIV的Apretude等专科药物，预计今年将实现低两位数的增长，成为推动业绩的主要动力。在疫苗领域，明星产品带状疱疹疫苗Shingrix创下了季度销售额纪录，为疫苗板块带来亮点。不过，受美国卫生部长Robert F. Kennedy Jr.对常规疫苗接种持怀疑态度的影响，市场分析师担忧美国免疫政策的变动将持续冲击葛兰素史克的疫苗业务。分析师指出，为充实研发管线，Miels预计将推行效率提升计划并加大交易并购力度。今年年初，葛兰素史克已同意以22亿美元收购专注于炎症和免疫疾病疗法的美国生物技术公司Rapt Therapeutics，并在另一笔交易中获得了一种治疗肺动脉高压的药物。展望未来，该公司重申了2026年全年业绩指引，预计销售额增长3%至5%，核心营业利润增长7%至9%。公司同时透露，随着计划新启动10项后期临床试验，今年新药研发支出的增速将超过销售额增速。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2631056182","isCrawlerRequest":true}

新掌门首份成绩单亮眼：HIV与抗癌药立功 葛兰素史克(GSK.US)Q1营收利润双超预期

精彩评论

新掌门首份成绩单亮眼：HIV与抗癌药立功葛兰素史克(GSK.US)Q1营收利润双超预期